SAN MATEO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Model N (NYSE: MODN), the leader in revenue optimization and compliance has introduced a critical product enhancement that supports evolving compliance needs around the Inflation Reduction Act (IRA). The company has introduced a new Medicare Part D inflation rebate-per-unit, ensuring pharma manufacturers remain compliant with impending IRA regulation and avoid significant revenue loss.

加利福尼亚州圣马特奥，2024年5月7日（环球通讯社）--收入优化和合规领域的领导者Model N（纽约证券交易所：MODN）推出了一项关键的产品改进，支持围绕《通货膨胀减少法案》（IRA）不断变化的合规需求。该公司推出了新的医疗保险D部分单位通货膨胀退税，确保制药制造商遵守即将出台的IRA法规，避免重大收入损失。

'The Inflation Reduction Act introduces sweeping changes for drug pricing and Medicare programs, and our goal is to empower customers to stay ahead of these shifts,' said Suresh Kannan, Chief Product Officer at Model N. 'As our life sciences customers prepare for new reforms and regulatory changes, Model N's latest product innovations address a critical market need by providing the capabilities necessary to calculate and process complex Medicare Part D inflation rebates.”  According to Model N’s 2024 State of Revenue Report, pharmaceutical executives are preparing for a significant revenue impact from the IRA.

Model N首席产品官苏雷什·坎南（SureshKannan）说：“通货膨胀减少法案为药品定价和医疗保险计划带来了全面的变化，我们的目标是让客户能够在这些变化之前保持领先。随着我们的生命科学客户为新的改革和监管变化做好准备，Model N最新的产品创新通过提供计算和处理复杂的医疗保险D部分通货膨胀回扣所需的能力来满足关键的市场需求。”根据Model N的2024年收入状况报告，制药高管正在准备IRA带来的重大收入影响。

The law aims to lower prescription drug costs for Medicare beneficiaries through provisions allowing the program to negotiate prices for certain high-cost drugs and requiring manufacturers to pay rebates for any price changes higher than the inflation rate. Effective for Medicare Part B and D drugs, manufacturers must calculate inflation penalties based on pricing increases over the designated benchmark periods.   Model N's new inflation rebate feature empowers customers to calculate Medicare Part D inflation rebate-per-unit, ensuring compliance with the upcoming IRA regulation set to take effect in 2025.

该法律旨在通过允许该计划谈判某些高成本药物的价格，并要求制造商为高于通货膨胀率的任何价格变化支付回扣，从而降低医疗保险受益人的处方药成本。对于医疗保险B部分和D部分药物有效，制造商必须根据指定基准期内的价格上涨计算通货膨胀罚款。 模型N的新通货膨胀返利功能使客户能够计算医疗保险D部分每单位的通货膨胀返利，确保符合即将于2025年生效的IRA法规。

Coupled with Model N's Government Pricing, Payer Management, Provider Management, and Validata solutions, customers gain a uni.

再加上Model N的政府定价、付款人管理、提供商管理和Validata解决方案，客户可以获得一个uni。